NCT03158779View on ClinicalTrials.gov

Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2022

Conditions
Pancreatic Cancer
Interventions
COMBINATION_PRODUCT

SBRT and chemotherapy

Patients affected by locally unresectable pancreatic cancer receive integrated treatment of FOLFIRINOX or Gemcitabine-Abraxane and a Stereotactic Body Radiation Therapy with a total dose of 54 Gy in 6 fractions of 9 Gy /fractions.

Trial Locations (1)

20089

Humanitas Research Hospital, Rozzano

All Listed Sponsors
lead

Istituto Clinico Humanitas

OTHER

NCT03158779 - Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter